Agree with your calc at 10 times sales (achieved sales FY2020). Based on run-rate and likely FY2021 sales, multiplier reduces to 7.5.Rokewa
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%